Outlook improves for patients with non-Hodgkin lymphoma over past decade

Five- and 10-year survival rates for patients with non-Hodgkin lymphoma appear to have increased from the 1990s to the early 21st century, according to a report in the March 10 issue of Archives of Internal Medicine.

Non-Hodgkin lymphoma includes several cancers of the immune system that occur in approximately 20.4 of every 100,000 individuals, according to background information in the article. Treatment for the condition has evolved rapidly in recent years.

Dianne Pulte, M.D., of the German Cancer Research Center, Heidelberg, and colleagues analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program of the U.S. National Cancer Institute. Survival rates were calculated based on two-year time periods between 1990 and 2004 within which patients were diagnosed with non-Hodgkin lymphoma, as well as by age group (15 to 44, 45 to 54, 55 to 64, 65 to 74 and 75 years or older), sex, race, tumor location (i.e. whether the disease was nodal [in the lymph nodes] or extranodal [in a site other than the lymph nodes]) and histologic subtype (to classify tumors as high-grade or low-grade).

“Overall, five-year relative survival increased from 50.4 percent to 66.8 percent, and 10-year relative survival increased from 39.4 percent to 56.3 percent between 1990 to 1992 and 2002 to 2004,” the authors write. “Improvements were most pronounced in patients younger than 45 years (plus 26.8 and plus 27.1 percentage points for five- and 10-year survival, respectively), but improvements were seen in all age groups, in both sexes, in both nodal and extranodal disease and in both low-grade and high-grade disease. Improvements in prognosis were less in black patients than in white patients, especially in younger black patients.”

Two factors may explain these improvements, the authors note. “One is advances in therapy that have occurred between 1990 and 2004, particularly the introduction of antibody therapy for non-Hodgkin lymphoma,” they write. “Treatment with antibody therapy and chemotherapy has extended life expectancy in many cases, but whether and how often this extension represents a true cure is still unknown.” In addition, improvements in the treatment of HIV have reduced the occurrence of HIV-related non-Hodgkin lymphomas and also made them easier to treat.

Source: JAMA and Archives Journals

Related stories:

Researchers solve piece of large-scale gene silencing mystery
A team led by Craig Pikaard, Ph.D., WUSTL professor of biology in Arts & Sciences, has made a breakthrough in understanding the phenomenon of nucleolar dominance, the silencing of an entire parental set of ribosomal RNA genes in a hybrid plant or animal.
Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder
Stem cells derived from bone marrow may serve as a novel therapeutic option to treat a disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile skin, according to a study prepublished online in Blood, the official journal of the American Society of Hematology.
Blood tests can help detect presence of necrotizing soft tissue infections
With less than half of patients with necrotizing soft tissue infections displaying the physical signs of these very serious infections, researchers have found two simple blood tests can help physicians diagnose what is commonly known as "flesh-eating bacteria," according to a study in the December issue of The American Journal of Surgery.
Novel basis identified for tamoxifen failure
Tamoxifen may worsen breast cancer in a small subset of patients. Research published in BioMed Central's open access journal Breast Cancer Research suggests that in patients who show reduced or absent expression of the protein E-cadherin, commonly used anti-oestrogen drugs such as tamoxifen may promote more harmful cancer cell behaviour.
Mayo Clinic identifies best treatments for long-term survival in brain tumor patients
A new Mayo Clinic study found that patients with low-grade gliomas survived longest when they underwent aggressive surgeries to successfully remove the entire tumor. If safely removing the entire tumor was not possible, patients survived significantly longer when surgery was followed by radiation therapy. This study is available online as an advance publication in Neuro-Oncology.
Cellular senescence a double-edged sword
Scientists have identified a molecular cause behind the ravages of old age and in doing so have also shown how a natural process for fighting cancer in younger persons can actually promote cancer in older individuals. Cellular senescence, the process by which biological cells stop dividing in response to stress or damage to their DNA, was shown to trigger the secretion of proteins that cause inflammation in neighboring cells and tissue. Inflammation is linked to almost every major disease associated with aging, including many cancers.
Study supports new standard of treatment for women with advanced ovarian cancer
Results of a phase III, international randomized clinical trial demonstrate a new standard of care for treating advanced ovarian cancer that significantly reduces side-effects and post-operative deaths compared to the previously established treatment course. The study, presented at the 12th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) in Bangkok in October, has a major impact on many countries where the new standard represents a more practical course of treatment.
New blood scanner detects even faint indicators of cancer
(PhysOrg.com) -- A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival.

News discussion:

Medicine & Health news